Dimensional Fund Advisors LP Has $18.73 Million Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Dimensional Fund Advisors LP grew its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) by 38.3% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 1,734,787 shares of the company’s stock after purchasing an additional 480,099 shares during the period. Dimensional Fund Advisors LP’s holdings in Allogene Therapeutics were worth $18,732,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. CI Investments Inc. boosted its holdings in shares of Allogene Therapeutics by 80.5% in the second quarter. CI Investments Inc. now owns 2,193 shares of the company’s stock worth $25,000 after buying an additional 978 shares during the period. Rockefeller Capital Management L.P. boosted its holdings in shares of Allogene Therapeutics by 9.7% in the third quarter. Rockefeller Capital Management L.P. now owns 14,083 shares of the company’s stock worth $151,000 after buying an additional 1,248 shares during the period. Oppenheimer & Co. Inc. boosted its holdings in shares of Allogene Therapeutics by 10.0% during the second quarter. Oppenheimer & Co. Inc. now owns 16,550 shares of the company’s stock worth $189,000 after purchasing an additional 1,500 shares during the period. US Bancorp DE boosted its holdings in shares of Allogene Therapeutics by 41.9% during the second quarter. US Bancorp DE now owns 5,474 shares of the company’s stock worth $63,000 after purchasing an additional 1,616 shares during the period. Finally, Allspring Global Investments Holdings LLC acquired a new stake in shares of Allogene Therapeutics during the third quarter worth approximately $34,000. 72.94% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Robert W. Baird upgraded shares of Allogene Therapeutics from a “neutral” rating to an “outperform” rating and set a $12.00 price target for the company in a report on Friday, January 6th. They noted that the move was a valuation call. The Goldman Sachs Group decreased their price target on shares of Allogene Therapeutics from $35.00 to $31.00 and set a “buy” rating for the company in a report on Wednesday, March 1st. EF Hutton Acquisition Co. I restated a “buy” rating and set a $15.00 price target on shares of Allogene Therapeutics in a report on Wednesday, March 1st. HC Wainwright decreased their price target on shares of Allogene Therapeutics from $43.00 to $29.00 and set a “buy” rating for the company in a report on Monday, November 21st. Finally, B. Riley cut their price objective on shares of Allogene Therapeutics from $18.00 to $15.00 in a research report on Wednesday, March 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, Allogene Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.67.

Allogene Therapeutics Stock Up 0.2 %

NASDAQ:ALLO opened at $5.96 on Wednesday. Allogene Therapeutics, Inc. has a 12 month low of $5.41 and a 12 month high of $17.49. The firm has a market cap of $861.22 million, a price-to-earnings ratio of -2.57 and a beta of 0.81. The company’s 50 day moving average is $6.80 and its 200-day moving average is $9.32.

Allogene Therapeutics (NASDAQ:ALLO – Get Rating) last released its quarterly earnings results on Tuesday, February 28th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.05. Allogene Therapeutics had a negative net margin of 136,885.59% and a negative return on equity of 43.44%. The company had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.06 million. During the same quarter last year, the firm posted ($0.54) earnings per share. The company’s quarterly revenue was down 6.0% compared to the same quarter last year. Research analysts predict that Allogene Therapeutics, Inc. will post -2.59 EPS for the current fiscal year.

Insider Transactions at Allogene Therapeutics

In other news, General Counsel Veer Bhavnagri sold 5,602 shares of the firm’s stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $7.53, for a total value of $42,183.06. Following the sale, the general counsel now owns 583,677 shares in the company, valued at $4,395,087.81. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last quarter, insiders have sold 11,602 shares of company stock worth $83,853. Insiders own 29.80% of the company’s stock.

About Allogene Therapeutics

(Get Rating)

Allogene Therapeutics, Inc operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.